CE-MS in biomarker discovery, validation, and clinical application


  • Harald Mischak,

    1. Mosaiques Diagnostics & Therapeutics, Hannover, Germany
    2. BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Search for more papers by this author
  • Joost P. Schanstra

    Corresponding author
    1. Inserm, Toulouse, France
    2. Université Toulouse III Paul Sabatier, Institut de Médecine Moléculaire de Rangueil, Toulouse, France
    • Inserm, U858/I2MR, 1 Avenue Jean Poulhès, BP 84225, 31432 Toulouse Cedex 4, France Fax: +33-562-17-25-54
    Search for more papers by this author

  • Colour Online: See the article online to view Figs. 1–6 in colour.


CE coupled MS (CE-MS) has become an increasingly employed technology in proteome analysis with focus on the identification of biomarker peptides in clinical proteomics. In this review, we will cover technical aspects of CE-MS coupling and highlight the improvements made in the last few years. We examine CE-MS from an application point of view, and evaluate its merits and vices for biomarker discovery and clinical applications. We discus the principal theoretical and practical obstacles encountered when employing CE-MS (and most other proteomic technologies) for the analysis of body fluids for biomarker discovery. We will present several examples of a successful application of CE-MS for biomarker discovery, implications for disease diagnosis, prognosis, and therapy evaluation, and will discuss current challenges and possible future improvements.